Last reviewed · How we verify
QR-bromocriptine
QR-bromocriptine, developed by the University of Texas Southwestern Medical Center, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | QR-bromocriptine |
|---|---|
| Also known as | NDC 6801225820, Cycloset (brand) |
| Sponsor | University of Texas Southwestern Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM (PHASE3)
- Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects (PHASE4)
- Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes (PHASE2)
- QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes (PHASE4)
- Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy (PHASE4)
- Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QR-bromocriptine CI brief — competitive landscape report
- QR-bromocriptine updates RSS · CI watch RSS
- University of Texas Southwestern Medical Center portfolio CI